EXEL - Exelixis again sues MSN Pharmaceuticals over Cabometyx generic

• Exelixis ( NASDAQ: EXEL ) is accusing MSN Pharmacueticals of patent infringement over its Abbreviated New Drug Application to market a generic of Cabometyx (cabozantinib).
• The lawsuit was filed Monday in a Delaware federal court.
• Exelixis is assert infringement of U.S. Patent No. 11,298,349, which expires on Feb. 10, 2032. The company said no Cabometyx generic approval should become valid until then.
• Worldwide revenue from the cabozantinib franchise (including Cometriq) reached more than $1.5B in 2021.
• This is not the first patent case Exelixis has filed against MSN in regards to Cabometyx as a trial began in May .

For further details see: